Tevogen CEO's Stock Gift Boosts Education for Underprivileged Youth

WARREN, N.J. – December 22, 2025 – Dr. Ryan Saadi, the Founder and CEO of clinical-stage biotechnology firm Tevogen Bio, has made a significant personal contribution to support youth education, donating 230,000 shares of his common stock in the company to SRLC USA, a United Nations-recognized nonprofit organization.

The donation, announced today from Tevogen’s headquarters, is earmarked to advance the educational initiatives of SRLC USA, which serves underprivileged communities across the United States and abroad. The move underscores a growing trend of corporate leaders leveraging personal assets to address pressing social issues, extending their impact far beyond the boardroom and laboratory.

“Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” Dr. Saadi stated in the official announcement. “I’m pleased to support an organization that is deeply committed to uplifting underserved communities through meaningful, measurable action.”

The Financial Impact and Recipient's Mission

Based on the closing price of Tevogen Bio’s stock (Nasdaq: TVGN) on December 22, 2025, which stood at $0.3851 per share, the donation is valued at approximately $88,573. For a nonprofit organization like SRLC USA, which operates as a 100% volunteer-driven entity, such a substantial infusion of capital can have a profound and immediate impact.

SRLC USA, also known as Shrimad Rajchandra Love and Care USA, has a strong reputation for fiscal responsibility and transparency. The organization holds a Platinum Seal of Transparency 2025 on Candid (formerly GuideStar) and a Three-Star rating from Charity Navigator, with high marks for accountability and finance. Its volunteer-based model, active in over 35 U.S. cities, ensures that administrative costs are kept low and a maximum percentage of donations goes directly to its charitable programs.

The funds from Dr. Saadi’s contribution are expected to directly bolster SRLC USA’s diverse educational programs. In the United States, these include annual “Back2School drives” that provide thousands of students with essential supplies like backpacks and notebooks. The organization also runs the SRLC Learning Education and Development (LEAD) program, offering academic coaching and training workshops for high school students and educators in underserved areas. Internationally, SRLC USA supports the establishment of schools and even a science university in rural India, creating pathways to higher education for tribal and rural youth who would otherwise lack such opportunities.

A Pattern of Philanthropy

This donation is not an isolated act of generosity from Dr. Saadi but rather the latest in a series of significant personal contributions made in late 2025. This pattern highlights a sustained commitment to community support that aligns with his publicly stated mission of fostering a more equitable society. All donations were conducted in accordance with SEC Rule 144, meaning Dr. Saadi will not receive any financial proceeds from the disposal of the shares, reinforcing the purely philanthropic nature of the gifts.

Just this month, Dr. Saadi has made several other notable stock donations:

• On December 11, he contributed 230,000 shares of Tevogen stock, valued at approximately $100,000 at the time, to the Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235 to support local law enforcement community initiatives.
• On December 19, he donated 50,000 shares, worth around $19,000, to the Mt. Bethel Fire Company to enhance emergency readiness in Warren Township, where Tevogen is headquartered.
• In August, he gifted 10,000 shares to the Opportunity Project, a New Jersey nonprofit dedicated to empowering individuals recovering from brain injuries.

This consistent pattern of giving reflects the philosophy of a leader who was nominated for the 2023 Nobel Peace Prize for a business model aimed at alleviating health inequality. Dr. Saadi’s actions suggest a belief that corporate leadership carries a responsibility that extends into the community, using personal success to fuel societal progress.

Beyond the Lab: A Socially Integrated Enterprise

Dr. Saadi’s personal philanthropy mirrors the corporate ethos of Tevogen Bio itself. The company defines itself as a “next-generation, socially integrated healthcare enterprise” built on principles of affordability and efficiency. Its stated mission is to broaden patient access to advanced therapies, disrupting a healthcare model often criticized for high costs and inequitable access.

Tevogen is developing cutting-edge treatments across virology, oncology, and neurology using its proprietary ExacTcell™ platform, which harnesses the power of precision T cell therapies. The company is also pioneering Tevogen.AI, an artificial intelligence platform designed to accelerate drug development, reduce failure rates, and optimize clinical trials. By collaborating with technology giants like Microsoft and Databricks, Tevogen aims to create a faster, more efficient path from discovery to patient care.

The leadership's focus on social good provides a compelling narrative for a company operating in the highly competitive and scrutinized biotech sector. By actively engaging in philanthropy that targets fundamental societal needs like education and public safety, Tevogen’s leadership reinforces its brand as one committed to more than just shareholder returns.

Executive Giving in the Biotech Sphere

The market registered a mild positive reaction to the news, with TVGN shares gaining 1.42% in a day of relatively light trading. While the immediate financial impact on the company’s valuation was modest, the long-term value of such actions often lies in building brand reputation and stakeholder trust.

Dr. Saadi's donations, while significant, differ in scale from the multi-billion-dollar pledges of CEOs from biotech giants like Moderna, whose fortunes swelled during the COVID-19 pandemic. However, the frequency and local focus of his giving create a distinct narrative of consistent, community-level engagement. This approach demonstrates a hands-on commitment to social responsibility that can resonate powerfully with employees, investors, and the public.

For a clinical-stage company like Tevogen, building a strong “social license to operate” is crucial. These philanthropic activities signal that the company’s mission of creating a more equitable healthcare system is not just a marketing slogan but a core value that permeates the organization from the top down. As Tevogen continues to advance its life-saving therapies, its leadership’s demonstrated commitment to community welfare provides a powerful complement to its scientific innovation, illustrating a modern vision where business success and societal benefit are inextricably linked.